We hope you are enjoying Optimum’s weekly newsletter – subscribe on LinkedIn today so you never miss an edition. Our clients Loqus23 Therapeutics and Ona Therapeutics continued the stream of good news for February with key leadership appointments. LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors LoQus23 Therapeutics Ltd, […]
There was a sense of tense anticipation at the end of 2024, amid signs that serious money was about to return to the biopharma industry. According to latest figures from BioWorld, January figures suggest that the big money is in licensing deals, as pharma companies snap up the latest drugs and therapies, rather than outright […]
To celebrate the International Day of Women & Girls in Science 2025, Optimum asked women in healthcare to share their favourite scientific advancement or innovation. From cloning Dolly the sheep, to CRISPR gene editing and the miracle of IVF, we received a wide variety of wonderful answers. Read the campaign below to find out what […]
Cell and gene therapies have had a tough few years. Investors, their heads turned by weight loss drugs and put off from taking longer-term bets by higher interest rates, appear to have hardly noticed them. The sector is certainly facing challenges – not only sentiment, but practical hurdles too. But is the wind about […]
There’s a new acronym that is causing mayhem throughout Washington – the EO (executive order). President Donald Trump signed 46 of them in January, with 26 signed during his first day in office on 20th January. While many EOs are subject to challenges in the courts, they show Trump’s determination to stamp his authority from […]
